Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASTA: ERAS vs ERAS plus artificial nutrition in open pancreatoduodenectomy
2020-005483-66Phase 3Completed
- Sponsor
- University of Milano-Bicocca
- Start
- Oct 2021
- Modality
- Device-based Delivery → Drug Delivery Systems, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of Peri-Olimel and Cernevit in Periampullary Carcinoma and pancreatic cancer (PC) (2 arms), sponsored by University of Milano-Bicocca. Primary endpoint: Comprehensive Complication Index within 30 days after hospital discharge. Started Oct 2021; status: completed.
02
Drugs
Peri-OlimelCernevit
03
Conditions
Periampullary Carcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on 2020-005483-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005483-66.